Skip to main navigation menu Skip to main content Skip to site footer

Author reply to technical comment

Vol. 153 No. 4 (2023)

Reply to comment by Suhm N on: Ferrari S, et al. 2020 recommendations for osteoporosis treatment according to fracture risk from the Swiss Association against Osteoporosis (SVGO)

  • Serge Ferrari
  • Christian Meier
DOI
https://doi.org/10.57187/smw.2023.40075
Cite this as:
Swiss Med Wkly. 2023;153:40075
Published
17.04.2023

Summary

No abstract available.

References

  1. Suhm N. Technical comment on: Ferrari S, et al. 2020 recommendations for osteoporosis treatment according to fracture risk from the Swiss Association against Osteoporosis (SVGO): Therapy of osteoporosis in the eldest geriatric patients – a plea for individualized decision-making. Swiss Med Wkly. 2023;153:40074. https://doi.org/10.57187/smw.2023.40074 DOI: https://doi.org/10.57187/smw.2023.40074
  2. Ferrari S, Lippuner K , Lamy O , Meier C . 2020 recommendations for osteoporosis treatment according to fracture risk from the Swiss Association against Osteoporosis (SVGO). Swiss Med Wkly. 2020 Sep;150(3940):w20352. https://doi.org/10.4414/smw.2020.20352 DOI: https://doi.org/10.4414/smw.2020.20352
  3. Lyles KW , Colón-Emeric CS , Magaziner JS , Adachi JD , Pieper CF , Mautalen C , et al.; HORIZON Recurrent Fracture Trial . Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007 Nov;357(18):1799–809. https://doi.org/10.1056/NEJMoa074941 DOI: https://doi.org/10.1056/NEJMoa074941

Most read articles by the same author(s)